Mode
Text Size
Log in / Sign up
Phase 3 Completed N=68 Treatment

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

Pantothenate Kinase-Associated Neurodegeneration
Source: ClinicalTrials.gov NCT02174848 ↗
Enrolled (actual)
68
Serious AEs
48.5%
Results posted
Jul 2019
Primary outcomePrimary: Number of Participants With Adverse Events — 22; 42; 12; 14 Participants
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Adverse Events
22; 42; 12; 14; 2; 1
SECONDARY
Change in Score on the BAD Scale -- Comparison of Treatment Groups Over Each Study
4.4; 1.9; 1.4; 1.4 0.0500
SECONDARY
Change in Score on the BAD Scale -- Comparison of Placebo-DFP Patients Across Studies
4.4; 1.4 0.0206 sig
SECONDARY
Change in Score on the BAD Scale -- Comparison of DFP-DFP Patients Across Studies
1.9; 1.4 0.2684
SECONDARY
Proportion of Patients With Improved or Unchanged BAD Score
3; 17; 9; 17 0.0821
SECONDARY
Patient Global Impression of Improvement (PGI-I) Comparison of Placebo-DFP Patients Across Studies
4.4; 4.7 0.3306

Eligibility Criteria

Inclusion Criteria

  • Completed study TIRCON2012V1

Exclusion Criteria

  • Withdrew from the study TIRCON2012V1 for reasons of safety
  • Plan to participate in another clinical trial at any time from the day of enrolment until 30 days post-treatment in the current study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02174848). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search